172 related articles for article (PubMed ID: 18221041)
21. Recent development of anti-cancer drugs for treatment of GI malignancies in Japan.
Taguchi T
Gan To Kagaku Ryoho; 2002 Feb; 29 Suppl 1():76-80. PubMed ID: 11890118
[No Abstract] [Full Text] [Related]
22. Recent developments towards podophyllotoxin congeners as potential apoptosis inducers.
Kamal A; Hussaini SM; Malik MS
Anticancer Agents Med Chem; 2015; 15(5):565-74. PubMed ID: 25469512
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in topoisomerase I-targeting agents, camptothecin analogues.
Kim DK; Lee N
Mini Rev Med Chem; 2002 Dec; 2(6):611-9. PubMed ID: 12370044
[TBL] [Abstract][Full Text] [Related]
24. Irinotecan (CPT-11): pharmacology and clinical applications.
Masuda N; Kudoh S; Fukuoka M
Crit Rev Oncol Hematol; 1996 Sep; 24(1):3-26. PubMed ID: 8869796
[No Abstract] [Full Text] [Related]
25. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
26. 20th-century advances in drug therapy in oncology--Part. II.
Dutcher JP; Novik Y; O'Boyle K; Marcoullis G; Secco C; Wiernik PH
J Clin Pharmacol; 2000 Oct; 40(10):1079-92. PubMed ID: 11028247
[TBL] [Abstract][Full Text] [Related]
27. Podophyllotoxin derivatives: a patent review (2012 - 2014).
Kamal A; Ali Hussaini SM; Rahim A; Riyaz S
Expert Opin Ther Pat; 2015; 25(9):1025-34. PubMed ID: 26027947
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
29. New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
Saijo N
Chest; 1998 Jan; 113(1 Suppl):17S-23S. PubMed ID: 9438685
[TBL] [Abstract][Full Text] [Related]
30. [A multivariate analysis approach to antineoplastic and antiviral structure-activity relationships to a series of podophyllotoxins].
Doré JC; Viel C; Pageot N; Gordaliza M; Castro A; del Corral JM; Feliciano AS
J Pharm Belg; 1996; 51(1):9-18. PubMed ID: 8882445
[TBL] [Abstract][Full Text] [Related]
31. A review of the clinical experience with irinotecan (CPT-11).
Horowitz RW; Wadler S; Wiernik PH
Am J Ther; 1997; 4(5-6):203-10. PubMed ID: 10423612
[TBL] [Abstract][Full Text] [Related]
32. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.
Lloyd Jones M; Hummel S; Bansback N; Orr B; Seymour M
Health Technol Assess; 2001; 5(25):1-128. PubMed ID: 11990245
[No Abstract] [Full Text] [Related]
33. New anticancer agents: taxol, camptothecin analogs, and anthrapyrazoles.
Hawkins MJ
Oncology (Williston Park); 1992 Dec; 6(12):17-23; discussion 27-30. PubMed ID: 1361358
[TBL] [Abstract][Full Text] [Related]
34. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.
Hartmann JT; Lipp HP
Drug Saf; 2006; 29(3):209-30. PubMed ID: 16524321
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy for newly diagnosed and relapsed advanced ovarian cancer.
Rose PG
Semin Oncol Nurs; 2003 Nov; 19(4 Suppl 2):25-35. PubMed ID: 14702918
[TBL] [Abstract][Full Text] [Related]
36. Clinical applications of anticancer drugs targeted to topoisomerase II.
Hande KR
Biochim Biophys Acta; 1998 Oct; 1400(1-3):173-84. PubMed ID: 9748560
[TBL] [Abstract][Full Text] [Related]
37. Unique biochemical, cytotoxic, and antitumor activity of camptothecin and 4beta-amino-4'-O-demethylepipodophyllotoxin conjugates.
Chang JY; Guo X; Chen HX; Jiang Z; Fu Q; Wang HK; Bastow KF; Zhu XK; Guan J; Lee KH; Cheng YC
Biochem Pharmacol; 2000 Mar; 59(5):497-508. PubMed ID: 10660116
[TBL] [Abstract][Full Text] [Related]
38. [Molecular targets in colon cancer].
Borner MM
Ther Umsch; 2006 Apr; 63(4):243-8. PubMed ID: 16689454
[TBL] [Abstract][Full Text] [Related]
39. Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells.
Puglisi F; Andreetta C; Valent F; Minisini AM; Rijavec E; Russo S; Mansutti M; Cardellino G; Pizzolitto S; Di Loreto C
Anticancer Drugs; 2007 Sep; 18(8):883-8. PubMed ID: 17667593
[TBL] [Abstract][Full Text] [Related]
40. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Burris HA; Fields SM
Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
